Invivo anti-Mouse CD8α Recombinant mAb, F(ab’)2 Fragment
Invivo anti-Mouse CD8α Recombinant mAb, F(ab’)2 Fragment
Product Details
Product Details
Product Specification
| Synonyms | T-cell surface glycoprotein CD8 alpha chain; T-cell surface glycoprotein Lyt-2; Lyt-2; Lyt2; Cd8a |
| Location | Cell membrane |
| Accession | P01731 |
| Clone Number | 2.43 |
| Antibody Type | Rat mAb |
| Isotype | Rat IgG2b, κ |
| Isotype Control | Invivo rat IgG2b isotype control, anti-keyhole limpet hemocyanin |
| Application | Functional Assay |
| Reactivity | Ms |
| Purification | Protein G |
| Concentration | 5 mg/ml |
| Purity | >95% (Determined by SDS-PAGE) |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
CD8α is a crucial immune glycoprotein that serves as a co-receptor for the MHC I-peptide complex, facilitating the recognition of antigens presented by APCs (antigen-presenting cells) to T cells. It is a key component of the CD8 receptor complex, which is predominantly found on cytotoxic T lymphocytes (CTLs). CD8α can form either an α/β heterodimer with CD8β or an α/α homodimer, both of which play essential roles in CTL activation and function. By interacting with the TCR (T cell receptor) and MHC I molecules, CD8α helps recruit the LCK kinase, initiating multiple signaling pathways that drive the CTL-mediated immune response.
This product is a F(ab) fragment derived from the anti-mouse CD8α antibody clone 2.43. Unlike full-length antibodies, this F(ab) fragment contains only the antigen-binding region and lacks the Fc domain, allowing specific binding to CD8α while eliminating Fc-mediated effects such as complement activation and Fcγ receptor engagement.
This Fc-free format is suitable for studies requiring CD8α targeting without inducing immune effector functions, antibody cross-linking, or CD8⁺ T cell depletion. It can also be applied in targeted delivery strategies, such as nanoparticle-based systems for selective CD8⁺ T cell targeting and in vivo delivery of genetic payloads.
